SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Abcam plc ABCM NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Abcam plc (ABCM) is a Biotechnology company in the Healthcare sector, currently trading at $23.99. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $362M, +28.4%/yr average growth. Net income is $9M (loss), growing at -19%/yr. Net profit margin is -2.4% (negative). Gross margin is 74.8% (+5.5 pp trend).

Balance sheet: total debt is $224M against $727M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 1.27 (adequate). Debt-to-assets is 21.2%. Total assets: $1.1B.

Analyst outlook: 1 / 5 analysts rate ABCM as buy (20%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 75/100 (Partial), Health 50/100 (Partial), Moat 70/100 (Pass), Future 20/100 (Fail), Income 10/100 (Fail).

ABCM SharesGrow Score Overview

47/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 70/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABCM

No analyst coverage available for this stock.

ABCM: +28.4%/yr revenue is, -19%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

ABCM: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet ABCM: Debt-to-Equity (D/E) ratio 0.31 (conservative), Current ratio is 1.27 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ABCM: Gross margin is 74.8% (+5.5 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 5 analysts rate ABCM as buy (20%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ABCM: Net profit margin is -2.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range12.48-25.32

Volume7.43M

Avg Volume (30D)5.82M

Market Cap$5.52B

Beta (1Y)0.86

Share Statistics

EPS (TTM)-0.04

Shares Outstanding$228.7M

IPO Date2020-10-22

Employees1,760

CEOAlan Thomas Hirzel BS,

Financial Highlights & Ratios

Revenue (TTM)$361.7M

Gross Profit$270.5M

EBITDA$42.7M

Net Income$-8.5M

Operating Income$-10.2M

Total Cash$89M

Total Debt$223.9M

Net Debt$134.9M

Total Assets$1.06B

Price / Earnings (P/E)-644.9

Price / Sales (P/S)15.26

Analyst Forecast

Rating ConsensusHold

Analysts Covering5

Buy 20% Hold 80% Sell 0%

Company Info

CountryGB

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS0003802040

Price Chart

ABCM

Abcam plc ↗ · NASDAQ Global Select

Healthcare • Biotechnology

12.48 52WK RANGE 25.32

People Also View

AnaptysBio, Inc.

Mineralys Therapeutics, Inc.

AN2 Therapeutics, Inc.

Aerovate Therapeutics, Inc.

Acrivon Therapeutics, Inc. Common Stock

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message